Article and Video CATEGORIES
Following the terrific presentations by Drs. Ben Solomon and Ross Camidge on the science and clinical experience with the novel ALK inhibitor XALKORI (crizotinib), we had a question and answer session, which is now available as a podcast. Here's the audio podcast and transcript for it (not really a video component for this one).
[powerpress]
drs-solomon-and-camidge-qa-on-alk-inhibition-transcript
Thanks to Drs. Solomon and Camidge for their participation, and to LUNGevity Foundation for partnering with us to make this program and so many others in the series of webinars and podcasts on lung cancer topics possible.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Caregiver and welcome to Grace. I'm sorry that you need to be here and hope we can help. Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...
Hi Bob, Welcome to Grace. I'm sorry about your sil. Unfortunately, cancer becomes resistant to TKIs like tagrisso. Sometimes all of the cancer becomes resistant at once and sometimes just parts...
Hi Kimberly, Welcome to Grace. I'm sorry you are here and glad you've found us.
It sounds like a biopsy would be the next step. I can't speak to what...